{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:46:00Z","timestamp":1792147560679,"version":"4.4.0"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["MRMC"],"published-print":{"date-parts":[[2026,10,12]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract:<\/jats:title>\n                    <jats:p>This review summarizes the structure-property relationships underlying 10 smallmolecule\ndrugs approved by the US FDA in 2025, with an emphasis on the lead optimization strategies\nthat facilitated their successful clinical advancement. Analysis of pharmacological and physicochemical\ndatasets revealed two recurrent optimization approaches that effectively addressed pharmacokinetic\nand toxicological liabilities during development. First, the deliberate incorporation or\nmodification of heterocyclic motifs enables the simultaneous optimization of multiple drug-like\nproperties. Representative examples include the N-methylpyrazole substituent in aficamten, which\nimproves oral bioavailability; substitution of a metabolically labile carbamate with a pyrimidine ring\nin avutometinib; and introduction of a methylated oxazolidinone moiety in zoliflodacin, which\nmarkedly increases aqueous solubility. Second, precise control of the hydrogen-bond donor count\nwas essential for optimizing membrane permeability and oral absorption. This was achieved either\nthrough N-methylation, as demonstrated by aficamten and vimseltinib, or through intramolecular\nhydrogen bonding via strategically positioned acceptor groups. In several cases, fluorine substitution\nadjacent to NH functionalities effectively masked donor characteristics, thereby improving permeability\nand overall pharmacokinetic performance. Collectively, these case studies underscore the value\nof rigorous structure-property relationship analysis integrated with established medicinal chemistry\nprinciples. Such approaches enable the successful navigation of complex lead-to-candidate optimization\nchallenges and provide practical guidance for future small-molecule drug discovery efforts.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0113895575494597260929085547","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:58:58Z","timestamp":1792144738000},"source":"Crossref","is-referenced-by-count":0,"title":["Structure-property Relationships Reported for the New Drugs Approved in 2025"],"prefix":"10.2174","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5196-4107","authenticated-orcid":true,"given":"Kihang","family":"Choi","sequence":"first","affiliation":[{"name":"Department of Chemistry, Korea University, Seoul 02841, Korea (ROK)"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","container-title":["Mini-Reviews in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113895575494597260929085547","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/259467\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113895575494597260929085547","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:59:13Z","timestamp":1792144753000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/259467\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,12]]},"references-count":0,"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0113895575494597260929085547","relation":{},"ISSN":["1389-5575"],"issn-type":[{"value":"1389-5575","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,12]]}}}